Chongqing Zhifei Biological Products Co., Ltd. (Zhifei) started to engage in the industry of biological products in 2002. Now, it has a registered capital of RMB 1.6 billion and over 2,400 employees as well as RMB 6.2 billion in assets. In September 2010, Zhifei was listed on the Shenzhen Stock Exchange (stock code: 300122), becoming the first privately-run vaccine enterprise listed on ChiNext. Zhifei has five wholly-owned subsidiaries and a joint-stock subsidiary, of which Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. are new high-tech enterprises.
As a high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use, which is one of seven strategic emerging industries of China and has a broad development prospect. Now, its independent products on sale include Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine,(MenAC-Hib) Haemophilus Influenzae Type b Conjugate Vaccine(Hib), Group ACYW135 Meningococcal Polysaccharide Vaccine (Menwayc®), Mycobacterium Vaccae for Injection (Vaccae®) and Meningococcal Group A and C Conjugate Vaccine (MeningACon®). Meantime,Zhifei is the sole distributor of the vaccines of Merck Sharp & Dohme (MSD) such as HPV4(Gradasil),HPV9(Gradasil 9),5-valent rotavirus vaccine(Rotateq),23-valent Pneumonia vaccine(Pneumovax 23),Hepatitis A vaccine(Vaqta).